<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amphotericin B nephrotoxicity</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amphotericin B nephrotoxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Amphotericin B nephrotoxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Perazella, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Amphotericin B is used in the treatment of often life-threatening fungal infections. Acute kidney injury (AKI) is a relatively common complication of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, as are other kidney manifestations, including urinary potassium wasting and hypokalemia, urinary magnesium wasting and hypomagnesemia, metabolic acidosis due to type 1 (or distal) renal tubular acidosis (RTA), and polyuria due to arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus). Lipid-based formulations of amphotericin B have reduced but not completely eliminated the risk of nephrotoxicity.</p><p>An overview of amphotericin B nephrotoxicity is presented here. The management of hypokalemia, hypomagnesemia, distal RTA, and AVP-R is discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults", section on 'Treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/834.html" rel="external">"Hypomagnesemia: Evaluation and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Distal (type 1) renal tubular acidosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2039467940"><span class="h1">ACUTE KIDNEY INJURY</span></p><p class="headingAnchor" id="H41481937"><span class="h2">Incidence and risk factors</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) is a common complication of conventional amphotericin B (ie, <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>) [<a href="#rid1">1-6</a>]. In the two largest reviews, a 50 percent or greater increase in serum creatinine was observed in 138 of 494 and 174 of 643 patients (28 and 27 percent, respectively) [<a href="#rid4">4,5</a>]. The incidence of nephrotoxicity is lower with lipid-based formulations of amphotericin B, as discussed below. (See <a class="local">'Use of lipid-based formulations'</a> below.)</p><p>The risk of amphotericin-induced kidney injury is influenced by other factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent therapy with other nephrotoxins, such as an aminoglycoside, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, or <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>, increases the risk of AKI [<a href="#rid4">4-7</a>]. In one report, the incidence of a twofold or greater increase in serum creatinine was 15 percent in patients taking no or one concurrent nephrotoxic drug and 41 percent in those taking two or more concurrent nephrotoxic drugs [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic kidney disease (CKD) at baseline and the severity of the underlying illness also increase the risk [<a href="#rid4">4,5</a>]. In one series, the incidence of moderate to severe nephrotoxicity (defined as a doubling of the serum creatinine to a level greater than 2 mg/dL) was 4 percent in patients with no risk factors for AKI and 8 to 29 percent in those with CKD [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The likelihood of kidney disease is also dose dependent, with the risk of kidney function impairment being low at doses of less than 0.5 mg/kg per day and a cumulative dose of less than 600 mg [<a href="#rid4">4,5,7</a>].</p><p></p><p>A prediction rule risk stratified patients based upon the following clinical data available during the course of therapy: location of care (general medical unit versus intensive care unit), concurrent use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and maximum daily amphotericin B dose (&lt;60 mg versus ≥60 mg daily). In the lowest risk group (12 percent of patients), the risk of nephrotoxicity was 4 percent, while in the highest risk group (10 percent of patients), the risk of AKI was 80 percent [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H1113941191"><span class="h2">Pathogenesis of AKI</span><span class="headingEndMark"> — </span>The original formulation of amphotericin B contains sodium deoxycholate to increase the solubility of amphotericin B in water. The hydrophobic part of the molecule binds to ergosterol, the main sterol in the cytoplasmic membrane of fungi. This forms pores and channels in the plasma membrane that allow the extravasation of electrolytes from the intracellular medium (such as potassium, ammonium, and phosphate) in addition to carbohydrate and proteins, thereby causing cell death. Besides its affinity for the fungal ergosterol, <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> also has affinity for cholesterol present in mammalian cells. Thus, in addition to its antifungal activity, amphotericin B causes substantial toxicity to mammalian cells, causing kidney, heart, and hematologic injury [<a href="#rid8">8-11</a>].</p><p>Proximal tubular cells and medullary interstitial cells respond with programmed cell death when treated with therapeutic doses of amphotericin B. In animal models, the number of apoptotic tubular cells correlates with the degree of hypokalemia and loss of renal concentrating ability; administration of insulin-like growth factor-1, an antiapoptotic agent, prevents hypokalemia and preserves concentrating ability [<a href="#rid12">12</a>]. In addition to this direct effect, in vitro studies suggest that approximately one-half of the tubular toxicity of amphotericin B may be mediated by deoxycholate [<a href="#rid8">8-11</a>].</p><p>The reduction in glomerular filtration rate (GFR) associated with amphotericin B-induced tubular toxicity may be mediated in part by the tubuloglomerular feedback (TGF) system [<a href="#rid1">1,13</a>]. Normally, when sodium chloride delivery to the distal tubule increases, a greater quantity of sodium chloride enters the macula densa cells located in the early portion of the distal tubule. This results in activation of a feedback loop (TGF), which triggers afferent arteriolar vasoconstriction and a fall in GFR [<a href="#rid1">1,13</a>]. Under most circumstances, this TGF response is physiologically appropriate: high rates of sodium chloride delivery out of the proximal tubule are restored to near normal levels by the appropriate reduction in GFR, and this prevents excessive sodium chloride losses in the urine [<a href="#rid14">14</a>]. However, amphotericin B nephrotoxicity increases the permeability of the macula densa cells. This may inappropriately activate the TGF system and lead to excessive afferent arteriolar vasoconstriction and a fall in GFR [<a href="#rid1">1,13</a>].</p><p>Alternatively, the renal vasoconstriction and fall in GFR may reflect a direct action of amphotericin B on blood vessels, rather than TGF [<a href="#rid15">15</a>]. In experimental animals, administration of a calcium channel blocker prevents amphotericin-induced vasoconstriction and the resultant decline in GFR [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H534156613"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Amphotericin B-associated AKI generally manifests with an increase in serum creatinine at four to five days following drug initiation, while hypokalemia and hypomagnesemia develop within or slightly after (seven to eight days) that time frame. However, these nephrotoxic events may occur before or after the noted times [<a href="#rid17">17,18</a>]. (See <a class="local">'Electrolyte and acid-base disorders'</a> below.)</p><p>In most cases, the serum creatinine increases by no more than 2.5 mg/dL (220 micromol/L) above baseline [<a href="#rid1">1,4,5,13</a>]. More severe kidney injury due to amphotericin B alone is uncommon but can occur with diuretic-induced volume depletion or the concurrent administration of another nephrotoxin.</p><p>The nephrotoxicity associated with amphotericin B is usually reversible with discontinuation of therapy [<a href="#rid13">13,19</a>]. However, recurrent AKI can occur if treatment is reinstituted [<a href="#rid19">19</a>]. There are no data on the long-term clinical course of patients following amphotericin B-associated AKI.</p><p class="headingAnchor" id="H1091662578"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>All patients receiving amphotericin B should be monitored for nephrotoxicity during therapy, particularly those with underlying risk factors. Electrolytes, blood urea nitrogen (BUN), and serum creatinine along with serum magnesium concentrations should be measured while on therapy with amphotericin B. (See <a class="local">'Incidence and risk factors'</a> above.) </p><p class="headingAnchor" id="H352234291"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>The risk of nephrotoxicity can be reduced by using lower doses of amphotericin and by avoiding concurrent therapy with other nephrotoxins, such as an aminoglycoside or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid4">4,5</a>]. Two other preventive measures are salt loading and the use of lipid formulations of amphotericin B. In addition, for some fungal infections, non-amphotericin B agents are now available.</p><p class="headingAnchor" id="H2019030256"><span class="h3">Salt loading</span><span class="headingEndMark"> — </span>For patients who are going to receive amphotericin B (conventional or lipid-based formulation) and who are not hypervolemic, we suggest volume expansion with isotonic fluids (typically isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) rather than more dilute fluids or no volume expansion to prevent the development of AKI. In patients who are euvolemic, a total of 500 mL of isotonic saline is typically given immediately prior to the amphotericin B infusion or divided before and after amphotericin B administration. Patients who are hypovolemic may require additional isotonic saline for volume repletion, while those who are hypervolemic should not receive isotonic saline prior to or after receiving amphotericin B.</p><p>The proposed importance of TGF in amphotericin B nephrotoxicity has led to the use of salt loading since volume expansion has been shown to reduce the sensitivity of the TGF system. Studies in both humans and animals have shown that <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> administration can protect against or ameliorate the amphotericin B-induced decline in GFR [<a href="#rid1">1,2,13,20</a>] but <strong>not</strong> the signs of tubular dysfunction described above [<a href="#rid20">20</a>]. (See <a class="local">'Pathogenesis of AKI'</a> above.)</p><p>The beneficial effect of salt loading was best shown in a controlled study of patients with mucocutaneous leishmaniasis who received a 10-week course of amphotericin B (average dose 50 mg per day, given three times per week) [<a href="#rid20">20</a>]. The serum creatinine concentration was stable with salt loading (1 liter of isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> over the 60 minutes prior to amphotericin B administration) but rose from 0.6 to 1 mg/dL (53 to 88 micromol/L) in patients given only water. The minor degree of kidney function impairment in the relatively healthy control group probably reflects in part the absence of potentiating factors, such as volume depletion or concurrent aminoglycoside therapy.</p><p>However, this benefit of salt loading does not prove that TGF, rather than vasoconstriction, is the major mechanism underlying the reduced GFR. Increases in the secretion of vasoconstrictors (angiotensin II and norepinephrine) and decreases in the secretion of the vasodilator atrial natriuretic peptide might modulate the constrictive effect of amphotericin B [<a href="#rid15">15</a>]; volume expansion could prevent these hormonal changes.</p><p class="headingAnchor" id="H2017274041"><span class="h3">Use of lipid-based formulations</span><span class="headingEndMark"> — </span>Administering amphotericin B in a lipid-based formulation can minimize, though not eliminate, the incidence and severity of nephrotoxicity. Two lipid-based amphotericin B formulations are available: <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> (ABLC) and <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (L-AMB). These formulations have largely supplanted the use of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> in resource-abundant countries. L-AMB may be less nephrotoxic than ABLC [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Lipid-based amphotericin B formulations'</a>.)</p><p>Data from randomized trials [<a href="#rid22">22-24</a>] and observational studies [<a href="#rid25">25-28</a>] suggest that administering amphotericin B in a lipid-based formulation can minimize, though not eliminate, the incidence and severity of nephrotoxicity. The best comparative data are reported in a meta-analysis of randomized trials that compared conventional amphotericin B with both <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (five trials, 1233 patients) and lipid emulsion amphotericin B (nine trials, 459 patients) [<a href="#rid22">22</a>]. Compared with conventional amphotericin B, the incidence of nephrotoxicity was reduced with the use of liposomal amphotericin B (15 versus 33 percent) or lipid emulsion amphotericin B (12 versus 31 percent).</p><p>The reason why lipid-based formulations are associated with less AKI is incompletely understood. However, two possibilities have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>The liposomal preparation does not contain deoxycholate, which (as noted above) has direct tubular toxicity [<a href="#rid8">8</a>]. (See <a class="local">'Pathogenesis of AKI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The liposomes may be preferentially distributed to the reticuloendothelial system, where amphotericin B can be transferred directly to trapped fungi with less delivery to other cholesterol-containing cells, such as those in the kidney [<a href="#rid9">9</a>].</p><p></p><p>As with <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, the risk of nephrotoxicity with lipid-based formulations is higher among patients concurrently treated with other potentially nephrotoxic drugs, including aminoglycosides, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) [<a href="#rid6">6,27,29,30</a>].</p><p class="headingAnchor" id="H805906972"><span class="h3">Preventive interventions of unclear benefit</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> has been shown to protect against amphotericin-induced nephrotoxicity in animal models, preserving GFR and reducing apoptosis of renal tubular cells [<a href="#rid31">31,32</a>]. Evidence for a protective role in humans, however, has been inconclusive [<a href="#rid33">33</a>].</p><p><a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> and <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> have also been employed for prophylaxis without success [<a href="#rid17">17,34</a>].</p><p>Continuous infusion of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> over 24 hours may help to minimize potentially nephrotoxic peak concentrations and decrease nephrotoxicity when compared with conventional infusion (over two to six hours) [<a href="#rid35">35-37</a>]. There are no studies comparing this approach with the use of lipid-based formulations of amphotericin B. </p><p class="headingAnchor" id="H3839171092"><span class="h2">Management of AKI</span><span class="headingEndMark"> — </span>For patients with amphotericin B-associated AKI, discontinuing amphotericin B and switching to another effective antifungal agent is appropriate. The general approach to the management of AKI after amphotericin administration is the same as that for other causes of AKI. These issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6090.html" rel="external">"Prevention and management of acute kidney injury (acute renal failure) in children"</a>.) </p><p class="headingAnchor" id="H591593608"><span class="h1">ELECTROLYTE AND ACID-BASE DISORDERS</span><span class="headingEndMark"> — </span>Amphotericin B has been associated with the following electrolyte and acid-base disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary potassium wasting and hypokalemia</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary magnesium wasting and hypomagnesemia</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic acidosis due to type 1 (or distal) renal tubular acidosis (RTA)</p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria due to arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus) </p><p></p><p class="headingAnchor" id="H72941557"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The increase in membrane permeability caused by amphotericin B is also thought to contribute to the electrolyte abnormalities that often occur. This defect results in the reduction of ion concentration gradients, which normally exist between the cytoplasm of distal tubule cells and the tubule lumen. In these cases, potassium leaks from the cytoplasm down a favorable concentration gradient into the lumen. Similarly, hydrogen ions diffuse down their gradient from the lumen into the cytoplasm of distal tubule cells [<a href="#rid38">38</a>]. Thus, an increase in tubular permeability will promote the back-diffusion of secreted hydrogen ions (or of carbonic acid formed by the combination of hydrogen with filtered bicarbonate), thereby limiting acid excretion [<a href="#rid39">39-41</a>]. Hypomagnesemia and renal magnesium wasting also occur as a result of amphotericin kidney toxicity [<a href="#rid41">41,42</a>]. </p><p>The loss of magnesium and potassium may also be related in part to the systemic toxicity of the amphotericin B that causes these intracellular ions to leak into the extracellular fluid space and then be lost into the urine [<a href="#rid2">2</a>].</p><p>The net effect of these changes is that both hypokalemia due to potassium loss and a normal anion gap metabolic acidosis (ie, a distal RTA) due to hydrogen retention are commonly seen [<a href="#rid2">2,6,38,40</a>]. Hypomagnesemia, though somewhat less common, is also reported. The distal RTA generated by amphotericin B, unlike most other forms of distal RTA, is associated with a normal urine-blood partial pressure of carbon dioxide (PCO<sub>2</sub>) after alkaline loading [<a href="#rid43">43,44</a>]. This likely results from the previously mentioned back-diffusion of secreted hydrogen ions, but a loss of polarity of the chloride-bicarbonate exchanger is also consistent with this finding [<a href="#rid43">43</a>].</p><p>Amphotericin B may also cause resistance to antidiuretic hormone, leading to polyuria and polydipsia [<a href="#rid2">2,6,44,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p class="headingAnchor" id="H2509786591"><span class="h2">Prevention and management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– As with acute kidney injury (AKI), the use of <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> may help to prevent electrolyte abnormalities and AVP-R [<a href="#rid6">6,46</a>]. In one randomized trial, patients receiving liposomal amphotericin B had a significantly lower rate of hypokalemia (serum potassium concentration ≤2.5 mEq/L) but no significant change in the rate of hypomagnesemia (serum magnesium concentration ≤1.5 mg/dL [0.6 mmol/L]) [<a href="#rid6">6</a>]. (See <a class="local">'Use of lipid-based formulations'</a> above.)</p><p></p><p class="bulletIndent1">If conventional amphotericin B is used, patients without significant kidney function impairment should receive daily preemptive administration of potassium, which may prevent serious hypokalemia due to urinary potassium wasting [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">In contrast to AKI, amphotericin B-induced electrolyte and acid-base abnormalities do not appear to be ameliorated by volume expansion [<a href="#rid20">20</a>]. (See <a class="local">'Salt loading'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– In general, treatment of the hypokalemia and RTA consists of administering alkali with potassium. Treatment of the magnesium wasting consists of the administration of magnesium supplements. However, the efficacy of this regimen is limited by the urinary excretion of most of the supplemental magnesium.</p><p></p><p class="bulletIndent1">Management of the electrolyte and acid-base disorders associated with amphotericin B is discussed in greater detail elsewhere:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypokalemia (see  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypomagnesemia (see  <a class="medical medical_review" href="/z/d/html/834.html" rel="external">"Hypomagnesemia: Evaluation and treatment", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Distal RTA (see  <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Management of distal RTA'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyuria due to arginine vasopressin resistance (see  <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>)</p><p></p><p class="headingAnchor" id="H2311582920"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110752.html" rel="external">"Society guideline links: Acute kidney injury in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110753.html" rel="external">"Society guideline links: Acute kidney injury in children"</a>.)</p><p class="headingAnchor" id="H3397838663"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney injury </strong>– Conventional amphotericin B (ie, <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>) commonly causes acute kidney injury (AKI). Lipid-based formulations of amphotericin B have reduced but not completely eliminated the risk of nephrotoxicity. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk factors </strong>– The risk of amphotericin B nephrotoxicity is increased by higher daily doses, longer duration of therapy, and concurrent therapy with other nephrotoxins, such as an aminoglycoside, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, or <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical presentation </strong>– Amphotericin B-associated AKI generally manifests with an increase in serum creatinine at four to five days following drug initiation, while hypokalemia and hypomagnesemia develop within or slightly after (seven to eight days) that time frame. However, these nephrotoxic events may occur before or after the noted times. The nephrotoxicity is usually reversible with discontinuation of therapy. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring </strong>– All patients receiving amphotericin B should be monitored for nephrotoxicity during therapy, particularly those with underlying risk factors. Electrolytes, blood urea nitrogen (BUN), and serum creatinine along with serum magnesium concentrations should be measured while on therapy with amphotericin B. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention </strong>– The risk of nephrotoxicity can be reduced by using lipid-based formulations of amphotericin B, lower doses of amphotericin, and by avoiding concurrent therapy with other nephrotoxins, such as an aminoglycoside or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. For patients who are going to receive amphotericin B (conventional or lipid-based formulation) and who are not hypervolemic, we suggest volume expansion with isotonic fluids (typically isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) rather than more dilute fluids or no volume expansion to prevent the development of AKI (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Salt loading'</a> above and <a class="local">'Use of lipid-based formulations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – For patients with amphotericin B-associated AKI, discontinuing amphotericin B and switching to another effective antifungal agent is appropriate. The general approach to the management of AKI after amphotericin administration is the same as that for other causes of AKI. (See  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6090.html" rel="external">"Prevention and management of acute kidney injury (acute renal failure) in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolyte and acid-base disorders</strong> – Amphotericin B can also cause urinary potassium wasting and hypokalemia, urinary magnesium wasting and hypomagnesemia, metabolic acidosis due to type 1 (or distal) renal tubular acidosis (RTA), and polyuria due to arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention </strong>– As with AKI, the use of <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> may help to prevent amphotericin B-associated electrolyte abnormalities and AVP-R. However, these abnormalities are not ameliorated by volume expansion. Patients without significant kidney function impairment who are receiving conventional amphotericin B are generally given daily potassium supplementation to prevent hypokalemia due to urinary potassium wasting. (See <a class="local">'Prevention and management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management </strong>– In general, treatment of the hypokalemia and RTA consists of administering alkali with potassium. Treatment of the magnesium wasting consists of the administration of magnesium supplements. However, the efficacy of this regimen is limited by the urinary excretion of most of the supplemental magnesium. (See <a class="local">'Prevention and management'</a> above.)</p><p></p><p class="headingAnchor" id="H145254615"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Richard Sterns, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148:2389.</a></li><li><a class="nounderline abstract_t">Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6:154.</a></li><li><a class="nounderline abstract_t">BUTLER WT, BENNETT JE, ALLING DW, et al. NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS. Ann Intern Med 1964; 61:175.</a></li><li><a class="nounderline abstract_t">Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528.</a></li><li><a class="nounderline abstract_t">Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001; 60:1452.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764.</a></li><li><a class="nounderline abstract_t">Fisher MA, Talbot GH, Maislin G, et al. Risk factors for Amphotericin B-associated nephrotoxicity. Am J Med 1989; 87:547.</a></li><li><a class="nounderline abstract_t">Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int 1992; 41:1588.</a></li><li><a class="nounderline abstract_t">Brüggemann RJ, Jensen GM, Lass-Flörl C. Liposomal amphotericin B-the past. J Antimicrob Chemother 2022; 77:ii3.</a></li><li><a class="nounderline abstract_t">Maertens J, Pagano L, Azoulay E, Warris A. Liposomal amphotericin B-the present. J Antimicrob Chemother 2022; 77:ii11.</a></li><li><a class="nounderline abstract_t">Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther 2021; 10:115.</a></li><li><a class="nounderline abstract_t">Varlam DE, Siddiq MM, Parton LA, Rüssmann H. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother 2001; 45:679.</a></li><li><a class="nounderline abstract_t">Heidemann HT, Gerkens JF, Spickard WA, et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75:476.</a></li><li><a class="nounderline abstract_t">Blantz RC, Pelayo JC. A functional role for the tubuloglomerular feedback mechanism. Kidney Int 1984; 25:739.</a></li><li><a class="nounderline abstract_t">Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991; 87:2097.</a></li><li><a class="nounderline abstract_t">Tolins JP, Raij L. Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade. J Am Soc Nephrol 1991; 2:98.</a></li><li><a class="nounderline abstract_t">Karimzadeh I, Sepehr-Sobhani A, Khoshnoud MJ, et al. Comparison of intravenous sodium bicarbonate and sodium chloride combination versus intravenous sodium chloride hydration alone in reducing amphotericin B nephrotoxicity: a randomized clinical trial. Res Pharm Sci 2020; 15:583.</a></li><li><a class="nounderline abstract_t">Gursoy V, Ozkalemkas F, Ozkocaman V, et al. Conventional Amphotericin B Associated Nephrotoxicity in Patients With Hematologic Malignancies. Cureus 2021; 13:e16445.</a></li><li><a class="nounderline abstract_t">Sacks P, Fellner SK. Recurrent reversible acute renal failure from amphotericin. Arch Intern Med 1987; 147:593.</a></li><li><a class="nounderline abstract_t">Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40:302.</a></li><li><a class="nounderline abstract_t">Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155.</a></li><li><a class="nounderline abstract_t">Mistro S, Maciel Ide M, de Menezes RG, et al. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 2012; 54:1774.</a></li><li><a class="nounderline abstract_t">Messori A, Fadda V, Maratea D, et al. Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis. Clin Infect Dis 2013; 57:1783.</a></li><li><a class="nounderline abstract_t">Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev 2015; 2015:CD010481.</a></li><li><a class="nounderline abstract_t">Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs Today (Barc) 2004; 40:133.</a></li><li><a class="nounderline abstract_t">Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31:780.</a></li><li><a class="nounderline abstract_t">Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40 Suppl 6:S414.</a></li><li><a class="nounderline abstract_t">White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24:635.</a></li><li><a class="nounderline abstract_t">Stanzani M, Vianelli N, Cavo M, et al. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Takazono T, Tashiro M, Ota Y, et al. Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan. Sci Rep 2020; 10:15033.</a></li><li><a class="nounderline abstract_t">Feldman L, Efrati S, Dishy V, et al. N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol 2005; 99:p23.</a></li><li><a class="nounderline abstract_t">Odabasi Z, Karaalp A, Cermik H, et al. Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine. Antimicrob Agents Chemother 2009; 53:3100.</a></li><li><a class="nounderline abstract_t">Karimzadeh I, Khalili H, Sagheb MM, Farsaei S. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity. Expert Opin Drug Metab Toxicol 2015; 11:1345.</a></li><li><a class="nounderline abstract_t">Panahi-Shokouh M, Moghaddas A, Badri S, et al. Pentoxifylline in Prevention of Amphotericin B-induced Nephrotoxicity and Electrolyte Abnormalities. J Res Pharm Pract 2020; 9:135.</a></li><li><a class="nounderline abstract_t">Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322:579.</a></li><li><a class="nounderline abstract_t">Geersing TH, Franssen EJF, Spronk PE, et al. Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching-authors' response. J Antimicrob Chemother 2022; 77:2309.</a></li><li><a class="nounderline abstract_t">Falagas ME, Karageorgopoulos DE, Tansarli GS. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis. PLoS One 2013; 8:e77075.</a></li><li><a class="nounderline abstract_t">Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969; 46:154.</a></li><li><a class="nounderline abstract_t">Gil FZ, Malnic G. Effect of amphotericin B on renal tubular acidification in the rat. Pflugers Arch 1989; 413:280.</a></li><li><a class="nounderline abstract_t">Batlle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986; 30:546.</a></li><li><a class="nounderline abstract_t">Atsmon J, Dolev E. Drug-induced hypomagnesaemia : scope and management. Drug Saf 2005; 28:763.</a></li><li><a class="nounderline abstract_t">Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 2000; 34:94.</a></li><li><a class="nounderline abstract_t">Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004; 38:1031.</a></li><li><a class="nounderline abstract_t">Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 2009; 5:193.</a></li><li><a class="nounderline abstract_t">Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984; 77:471.</a></li><li><a class="nounderline abstract_t">Canada TW, Weavind LM, Augustin KM. Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus. Ann Pharmacother 2003; 37:70.</a></li><li><a class="nounderline abstract_t">Bicanic T, Bottomley C, Loyse A, et al. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother 2015; 59:7224.</a></li></ol></div><div id="topicVersionRevision">Topic 2364 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3056312" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579079" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14204856" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705428" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576359" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Correlates of acute renal failure in patients receiving parenteral amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10072411" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2816970" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for Amphotericin B-associated nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1501413" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36426673" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Liposomal amphotericin B-the past.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36426672" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Liposomal amphotericin B-the present.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33523419" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181342" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Apoptosis contributes to amphotericin B-induced nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614033" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Amphotericin B nephrotoxicity in humans decreased by salt repletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6381854" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A functional role for the tubuloglomerular feedback mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1710234" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1912413" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33828601" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of intravenous sodium bicarbonate and sodium chloride combination versus intravenous sodium chloride hydration alone in reducing amphotericin B nephrotoxicity: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34422476" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Conventional Amphotericin B Associated Nephrotoxicity in Patients With Hematologic Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3827439" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recurrent reversible acute renal failure from amphotericin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1942779" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of salt supplementation on amphotericin B nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073745" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491505" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140972" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26595825" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15045035" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lipid-based formulations of amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9590187" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal effects of amphotericin B lipid complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809928" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Study of renal safety in amphotericin B lipid complex-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145737" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28607011" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32929112" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637469" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414577" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26050706" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33489981" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pentoxifylline in Prevention of Amphotericin B-induced Nephrotoxicity and Electrolyte Abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238151" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35781512" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching-authors' response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24204739" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4951424" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nephrotoxic effects of amphotericin B, including renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2717375" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of amphotericin B on renal tubular acidification in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3784293" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Segmental characterization of defects in collecting tubule acidification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16119971" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Drug-induced hypomagnesaemia : scope and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669191" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113987" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antimicrobial-associated renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19322184" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fluid, electrolyte and acid-base disorders associated with antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6475987" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Renal magnesium wasting associated with amphotericin B therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12503936" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26349818" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
